Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Germline genetic factors influence the outcome of interferon-α therapy in polycythemia vera.

Blood - 21 Jan 2021

Jäger Roland, Gisslinger Heinz, Fuchs Elisabeth, Bogner Edith, Milosevic Feenstra Jelena D, Weinzierl Jakob, Schischlik Fiorella, Gisslinger Bettina, Schalling Martin, Zörer Michael, Krejcy Kurt, Klade Christoph, Kralovics Robert

Abstract excerpt

Interferon-α (IFN-α)-based treatments can induce hematologic and molecular responses (HRs and MRs, respectively) in polycythemia vera (PV); however, patients do not respond equally. Germline genetic factors have been implicated in differential drug responses. We addressed the effect of common germline polymorphisms on HR and MR after treatment of PV in the PROUD-PV and CONTINUATION-PV studies in a total of 122...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Follow-Up Studies
Share to Germ Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interleukins

Share to Open Reading Frames

Share to Polycythemia Vera

Share to Polymorphism, Single Nucleotide

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 32814349
DOI: 10.1182/blood.2020005792
PMCID: PMC7980276

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Germline genetic factors influence the outcome of interferon-α therapy in polycythemia vera.PMID 32814349Read ↗

Pegylated interferon: the who, why, and howSemantic proximity Read ↗

Deciphering the complex clonal heterogeneity of polycythemia vera and the response to interferon alphaSemantic proximity Read ↗

The Mutational Landscape in Polycythemia Vera: Phenotype, Genotype, and Prognostic Correlates.Semantic proximity Read ↗

Genetic variation in IL28B (IFNL3) and response to interferon-alpha treatment in myeloproliferative neoplasms.Semantic proximity Read ↗

Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study.Semantic proximity Read ↗

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?Semantic proximity Read ↗

Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.Semantic proximity Read ↗

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.Semantic proximity Read ↗

A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.Semantic proximity Read ↗

Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses.Semantic proximity Read ↗

Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.Semantic proximity Read ↗

Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.